Physician profile
Christa Bowes
NPI 1023420627
$484.90
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $144.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $130.35 | 2019 | |
| Abbvie INC. | $83.16 | 2019-2020 | |
| Insulet Corporation | $49.26 | 2019 | |
| Eisai INC. | $47.13 | 2020 | |
| Shire North American Group INC | $47.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $47.00 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $24.33 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.66 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.17 | 2020 | |
| Pfizer INC. | $12.96 | 2019 | |
| Lilly USA, LLC | $11.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Bowes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.